A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment

Journal of Biotechnology

Volumn 221, Issue , 2016, Pages 1-12

  Gramlich, Paul A ^a,b   Westbroek, Wendy ^c   Feldman, Ricardo A ^d   Awad, Ola ^d   Mello, Nicholas ^b,d   Remington, Mary P ^b   Sun, Ying ^e,f   Zhang, Wujuan ^e   Sidransky, Ellen ^c   Betenbaugh, Michael J ^a   Fishman, Paul S ^b,d  

^a Johns Hopkins University   (United States)

^b Veteran Affairs Maryland Health Care System   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Gaucher's disease (GD); Glucocerebrosidase; Linker design; Rabies derived peptide

Indexed keywords

BINS; CELL CULTURE; DISEASE CONTROL; ENZYMES; MAMMALS; PEPTIDES; PROTEINS; RECOMBINANT PROTEINS;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; ENZYME REPLACEMENT THERAPY; FUNCTIONAL ENZYMES; GAUCHER'S DISEASE; GLUCOCEREBROSIDASE; MEMBRANE BINDING; NEURONAL MEMBRANES;

NEURONS;

GLUCOSYLCERAMIDASE; GLYCOPROTEIN; IMIGLUCERASE; IMMUNOGLOBULIN A; PEPTIDE; RABIES GLYCOPROTEIN DERIVED PEPTIDE; RECOMBINANT ENZYME; RECOMBINANT GLUCOCEREBROSIDASE; RECOMBINANT PROTEIN; TAT PEPTIDE; TETANUS LIKE PEPTIDE; TETANUS TOXIN; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PSYCHOSINE; SPHINGOSYL BETA-GLUCOSIDE;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; HINGE REGION; HUMAN; HUMAN CELL; MEMBRANE BINDING; NERVE CELL; NERVE CELL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; BLOOD BRAIN BARRIER; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM;

BLOOD-BRAIN BARRIER; CELLS, CULTURED; DRUG DESIGN; GLUCOSYLCERAMIDASE; HEK293 CELLS; HUMANS; NEURONS; PEPTIDE FRAGMENTS; PSYCHOSINE; RECOMBINANT PROTEINS;

EID: 84955290115     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2016.01.015     Document Type: Article

References (68)

1. Arai R., Ueda H., Kitayama A., Kamiya N., Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001, 14:529-532.
2. Berg-Fussman A., Grace M.E., Ioannou Y., Grabowski G.A. Human acid beta-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J. Biol. Chem. 1993, 268:14861-14866.
3. Bhandari D.G., Levine B.A., Trayer I.P., Yeadon M.E. 1H NMR study of motility and conformational constraints within the proline-rich N-terminal of the LC1 alkali light chain of skeletal myosin. Eur. J. Biochem. 1986, 160:349-356.
4. Böckenhoff A., Cramer S., Wölte P., Knieling S., Wohlenberg C., Gieselmann V., Galla H.J., Matzner U. Comparison of five peptide delivery vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A. J. Neurosci. 2014, 34:3122-3129.
5. Branco Novo J., Morganit L., Maria Moro A., Paes Leme A.F., de Toledo Serrano S.M., Raw I., Ho P.L. Generation of Chinese Hamster Ovary cell line producing recombinant human glucocerebrosidase. J. Biomed. Biotechnol. 2012, 10.1155/2012/875383.
6. Cabrera-Salazar M.A., Bercury S.D., Ziegler R.J., Marshall J., Hodges B.I., Chuang W.L., Pacheco J., Li L., Cheng S.H., Scheule R.K. Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease. Exp. Neurol. 2010, 225:436-444.
7. Cabrera-Salazar M.A., DeRiso M., Bercury S.D., Li L., Lydon J.T., Weber W., Pande N., Cromwell M.A., Copeland D., Leonard J., Cheng S.H., Scheule R.K. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One 2012, 10.1371/journal.pone.0043310.
8. Calvo A.C., Oliván S., Manzano R., Zaragoza P., Aguilera J., Osta R. Fragment C of tetanus toxin: new insights into its neuronal signaling pathway. Int. J. Mol. Sci. 2012, 13:6883-6901.
9. Chauhan A., Tikoo A., Kapur A.K., Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control. Release 2007, 17:148-162.
10. Chen X., Zaro J.L., Shen W.C. Fusion protein linkers: property, design, and functionality. Adv. Drug Deliv. Rev. 2013, 65:1357-1369.
11. Cromey D.W. Avoiding twisted pixels: ethical guidelines for the appropriate use and manipulation of scientific digital images. Sci. Eng. Ethics 2010, 16:639-667.
12. Deshayes S., Morris M.C., Divita G., Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 2005, 62:1839-1849.
13. Ebert A.D., McMillan E.L., Svendsen C.N. Isolating, expanding, and infecting human and rodent fetal neural progenitor cells. Curr. Protoc. Stem Cell Biol. 2008, 10.1002/9780470151808.sc02d02s6.
14. Erickson A., Bembi B., Schiffmann R. Neuronopathic forms of Gaucher's disease. Baillieres Clin. Haematol. 1997, 10:711-723.
15. Evans J.S., Levine B.A., Trayer I.P., Dorman C.J., Higgins C.F. Sequence-imposed structural constraints in the TonB protein of E coli. FEBS Lett. 1986, 208:211-216.
16. Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type 1. Ther. Clin. Risk Manage. 2008, 4:425-431.
17. Francis J.W., Brown R.H., Figueiredo D., Remington M.P., Castillo O., Schwarzschild M.A., Fishman P.S., Murphy J.R., vanderSpek J.C. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J. Neurochem. 2000, 74:2528-2536.
18. Francis J.W., Bastia E., Matthews C.C., Parks D.A., Schwarzschild M.A., Brown R.H., Fishman P.S. Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS. Brain Res. 2004, 1011:7-13.
19. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
20. Federici T., Liu J.K., Teng Q., Yang J., Boulis N.M. A means for targeting therapeutics to peripheral nervous system neurons with axonal damage. Neurosurgery 2007, 60:911-918.
21. Fu A., Wang Y., Zhan L., Zhou R. Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide. Pharm. Res. 2012, 29:1562-1569.
22. Fu A., Zhang M., Gao F., Xu X., Chen Z. A novel peptide delivers plasmids across blood-brain barrier into neuronal cells as a single-component transfer vector. PLoS One 2013, 10.1371/journal.pone.
23. Fu A., Zhao Z., Gao F., Zhang M. Cellular uptake mechanism and therapeutic utility of a novel peptide in targeted-delivery of proteins into neuronal cells. Pharm. Res. 2013, 30:2108-2117.
24. Gao Y., Wang Z.Y., Zhang J., Zhang Y., Huo H., Wang T., Jiang T., Wang S. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules 2014, 15:1010-1018.
25. George R.A., Heringa J. An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng. 2003, 15:871-879.
26. Georgieva J.V., Brinkhuis R.P., Stojanov K., Weijers C., Zuilhof H., Rutjes F., Hoekstra D., van Hest J., Zuhorn I.S. Peptide-mediated blood-brain barrier transport of polymersomes. Angew. Chem. Int. Ed. 2012, 51:8339-8342.
27. Gillmeister M.P., Betenbaugh M.J., Fishman P.S. Cellular trafficking and photochemical internalization of cell penetrating peptide linked cargo proteins: a dual fluorescent labeling study. Bioconjug. Chem. 2011, 22:556-566.
28. Gong C., Li X., Xu L., Zhang Y.H. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials 2012, 33:3456-3463.
29. Grace M.E., Newman K.M., Scheinker V., Berg-Fussman A., Grabowski G.A. Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression. J. Biol. Chem. 1994, 269:2283-2291.
30. Gramlich P.A., Remington M.P., Amin J., Betenbaugh M.J., Fishman P.S. Tat-tetanus toxin fragment C: a novel protein delivery vector and its use with photochemical internalization. J. Drug. Target. 2013, 21:662-674.
31. Grubb J.H., Volger C., Sly W.S. New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res. 2010, 13:229-236.
32. Hallewell R.A., Laria I., Tabrizi A., Gunnar C., Getzoff E.D., Tainer J.A., Cousena L.S., Mullenbach G.T. Genetically engineered polymers of human CuZn superoxide dismutase. J. Biol. Chem. 1989, 264:5260-5268.
33. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157:195-206.
34. Jin G., Zhu G., Zhao Z., Liu F. VP22 enhances the expression of glucocerebrosidase in human gaucher II fibroblast cells mediated by lentiviral vectors. Clin. Exp. Med. 2012, 12:135-143.
35. Klement M., Li C., Loo B.L.W., Choo A.B., Ow D.S., Lee D. Effect of linker flexibility and length on the functionality of a cytotoxic engineered antibody fragment. J. Biotechnol. 2015, 199:90-97.
36. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-45.
37. Lee K.O., Luu N., Kaneski C.R., Schiffmann R., Brady R.O., Murray G.J. Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 Tat protein transduction domain. Biochem. Biophys. Res. Commun. 2005, 337:701-707.
38. Lentz T.L. Rabies virus binding to an acetylcholine receptor α-subunit peptide. J. Mol. Recognit. 1990, 3:82-88.
39. Li J., Chian R.J., Ay I., Celia S.A., Kashi B.B., Tamrazian E., Matthews J.C., Remington M.P., Pepinsky R.B., Fishman P.S., Brown R.H., Francis J.W. Recombinant GDNF: tetanus toxin fragment C fusion protein produced from insect cells. Biochem. Biophys. Res. Commun. 2009, 385:380-384.
40. Liu Y., Huang R., Han L., Ke W., Shao K., Ye L., Lou J., Jiang C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 2009, 30:4195-4202.
41. Lonser R.R., Walbridge S., Murray G.J., Aizenberg M.R., Vortmeyer A.O., Aerts J.M.F.G., Brady R.O., Oldfield E.O. Convention perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann. Neurol. 2005, 57:542-548.
42. Lonser R.R., Schiffman R., Robison R.A., Butman J.A., Quezado Z., Walker M.L., Morrison P.F., Walbridge S., Murray G.J., Park D.M., Brady R.O., Oldfield E.O. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology 2007, 68:254-261.
43. Low T., Liu Y.S.V., Putnam F.W. Structure, function, and evolutionary relationships of Fc domains of human immunoglobulins A, G, M, and E. Science 1976, 191:390-392.
44. Mello, N., Gramlich, P.A., Remington, M.P., Fishman, P.S., 2015. Rabies glycoprotein derived peptide shows enhanced neuronal internalization of GFP compared to tetanus toxin fragment C, Tat, and Tet-1. Unpublished results, (in preparation).
45. Miana-Mena F.J., Roux S., Benichou J., Osta R., Brulet P. Neuronal activity-dependent membrane traffic at the neuromuscular junction. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3234-3239.
46. Panicker L.M., Miller D., Park T.S., Patel B., Azevedo J.L., Awad O., Masood M.A., Veenstra T.D., Goldin E., Stubblefield B.K., Tayebi N., Polumuri S.K., Vogel S.N., Sidransky E., Zambidis E.T., Feldman R.A. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:18054-18059.
47. Panicker L.M., Miller D., Awad O., Bose V., Lun Y., Park T.S., Zambidis E.T., Sgambato J.A., Feldman R.A. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells 2014, 32:2338-2349.
48. Pastores G.M. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs 2010, 24:41-47.
49. Poole R.M. Eliglustat: first global approval. Drugs 2014, 74:1829-1836.
50. Schueler U., Kaneski C., Murray G., Sandhoff K., Brady R.O. Uptake of mannose-terminal glucocerebrosidase in cultured human cholinergic and dopaminergic neuron cell lines. Neurochem. Res. 2002, 27:325-330.
51. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
52. Shaaltiel Y., Bartfield D., Hashmueli S., Baum G., Brill-Almon E., Galili G., Dym O., Boldin-Adamsky S.A., Silman I., Sussman J.L., Futerman A.H., Aviezer D. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 2007, 5:579-590.
53. Spencer B.J., Verma I.M. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7594-7599.
54. Sun Y., Liou B., Xu Y.H., Quinn B., Zhang W., Hamler R., Setchell K.D.R., Grabowski G.A. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J. Biol. Chem. 2012, 287:4275-4287.
55. Sun Y., Zhang W., Xu Y.H., Quinn B., Dasgupta N., Liou B., Setchell K.D.R., Grabowski G.A. March 8,. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models-implications for Gaucher Disease. PLoS One 2013, 10.1371/journal.pone.0057560.
56. Tekoah Y., Tzaban S., Kizhner T., Hainrichson M., Gantman A., Golembo M., Avioezer D., Shaaltiel Y. Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci. Rep. 2013, 10.1042/BSR20130081.
57. Turner S.L., Russell G.C., Williamson M.P., Guest G.R. Restructuring an interdomain linker in the dihydrolipoamide acetyltransferase component of the pyruvate dehydrogenase complex of Escherichia coli. Protein Eng. 1993, 6:101-108.
58. Tybulewicz V.L., Tremblay M.L., LaMarca M.E., Willemsen R., Stubblefield B.K., Winfield S., Zablocka B., Sidransky E., Martin B.M., Huang S.P. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 1992, 357:407-410.
59. Vaags A.K., Campbell T.N., Choy F.Y.M. HIV Tat variants differentially influence the production of glucocerebrosidase in Sf9 cells. Genet. Mol. Res. 2005, 4:491-495.
60. Van Patten S.M., Hughes H., Huff M.R., Piepenhagen P.A., Waire J., Qiu H., Chandrashekar G., Reczek D., Ward P.V., Kutzko J.P., Edmunds T. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007, 17:467-478.
61. Westbroek, W., Nguyen, M., Burnett, R., Siebert, M., Aflaki, E., Behre, B., Costa, W., Rodriguez-Gil, J., Fujiwara, H., Sidhu, R., Tayebi, N., Renvoise, B., Cramer, C., Pavan, W., Ory, D., Sidransky, E., 2015. A novel neuronal cell model for Gaucher type II. Unpublished results, (in preparation).
62. Xia H., Mao Q., Davidson B.L. The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 2001, 19:640-644.
63. Xiang L., Zhou R., Fu A., Xu X., Huang Y., Hu C. Targeted delivery of large fusion protein into hippocampal neurons by systemic administration. J. Drug Target. 2011, 19:632-636.
64. Yeh F.L., Dong M., Yao J., Tepp W.H., Lin G., Johnson E.A., Chapman E.R. SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog. 2010, 10.1371/journal.ppat.1001207.
65. Yu K., Liu C., Kim B.G., Lee D.Y. Synthetic fusion protein design and applications. Biotechnol. Adv. 2015, 33:155-164.
66. Zhang J., Yun J., Shang Z., Zhang X., Pan B. Design and optimization of a linker for fusion protein construction. Prog. Nat. Sci. 2009, 19:1197-1200.
67. Zhang X.Y., Dinh A., Cronin J., Li S.C., Reiser J. Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain. J. Neurochem. 2008, 104:1055-1064.
68. Zorko M., Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 2005, 57:529-545.